Richard Turnage
Concepts (485)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Intestines | 18 | 1998 | 169 | 1.680 |
Why?
| Reperfusion Injury | 17 | 2005 | 87 | 1.570 |
Why?
| General Surgery | 4 | 2014 | 106 | 0.890 |
Why?
| Capillary Permeability | 8 | 2003 | 35 | 0.760 |
Why?
| Tumor Necrosis Factor-alpha | 6 | 2003 | 388 | 0.740 |
Why?
| Lung | 13 | 2003 | 501 | 0.660 |
Why?
| Rats | 32 | 2005 | 3273 | 0.540 |
Why?
| Neutrophils | 6 | 2002 | 148 | 0.540 |
Why?
| Rats, Sprague-Dawley | 27 | 2005 | 1578 | 0.540 |
Why?
| Burns | 4 | 2003 | 165 | 0.540 |
Why?
| Ischemia | 7 | 1998 | 153 | 0.530 |
Why?
| Keratinocytes | 3 | 2001 | 90 | 0.500 |
Why?
| Thromboxane A2 | 4 | 2002 | 16 | 0.480 |
Why?
| Pulmonary Circulation | 6 | 2003 | 34 | 0.480 |
Why?
| Endothelium, Vascular | 7 | 2003 | 251 | 0.470 |
Why?
| Private Practice | 1 | 2014 | 10 | 0.470 |
Why?
| Financial Management | 1 | 2014 | 10 | 0.470 |
Why?
| Internship and Residency | 3 | 2014 | 442 | 0.460 |
Why?
| Education, Medical, Graduate | 3 | 2014 | 211 | 0.440 |
Why?
| Dinoprostone | 7 | 2000 | 48 | 0.430 |
Why?
| Microcirculation | 8 | 2006 | 71 | 0.430 |
Why?
| Nitric Oxide | 4 | 2006 | 253 | 0.420 |
Why?
| Pulmonary Edema | 4 | 1998 | 20 | 0.380 |
Why?
| Oxidants | 3 | 2006 | 54 | 0.370 |
Why?
| Epoprostenol | 8 | 2000 | 25 | 0.370 |
Why?
| Animals | 40 | 2006 | 13100 | 0.370 |
Why?
| Splanchnic Circulation | 5 | 1998 | 39 | 0.360 |
Why?
| Protein-Tyrosine Kinases | 2 | 2001 | 95 | 0.350 |
Why?
| Liability, Legal | 1 | 2009 | 12 | 0.320 |
Why?
| Malpractice | 1 | 2009 | 15 | 0.320 |
Why?
| Insurance Claim Review | 1 | 2009 | 36 | 0.320 |
Why?
| Medical Errors | 1 | 2009 | 24 | 0.320 |
Why?
| Nitric Oxide Synthase | 5 | 2006 | 73 | 0.310 |
Why?
| Cell Membrane Permeability | 2 | 2006 | 28 | 0.310 |
Why?
| Reperfusion | 3 | 1996 | 14 | 0.290 |
Why?
| Colorectal Neoplasms | 2 | 2001 | 253 | 0.280 |
Why?
| Endothelial Cells | 2 | 2006 | 256 | 0.280 |
Why?
| Attitude of Health Personnel | 1 | 2009 | 349 | 0.250 |
Why?
| Cadherins | 2 | 2002 | 64 | 0.250 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2003 | 154 | 0.250 |
Why?
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2002 | 4 | 0.230 |
Why?
| Liver | 5 | 2004 | 1106 | 0.230 |
Why?
| Male | 39 | 2011 | 25454 | 0.230 |
Why?
| Humans | 45 | 2017 | 49929 | 0.220 |
Why?
| Duodenal Ulcer | 1 | 2003 | 12 | 0.220 |
Why?
| Gelsolin | 1 | 2003 | 2 | 0.220 |
Why?
| Insulin | 1 | 2006 | 453 | 0.220 |
Why?
| Cells, Cultured | 8 | 2006 | 1587 | 0.210 |
Why?
| Colonic Neoplasms | 2 | 2003 | 158 | 0.200 |
Why?
| Thromboxane B2 | 4 | 1998 | 8 | 0.200 |
Why?
| Respiratory Mucosa | 1 | 2002 | 10 | 0.200 |
Why?
| Pneumonia | 1 | 2003 | 117 | 0.200 |
Why?
| Antigens, CD | 3 | 2002 | 215 | 0.200 |
Why?
| Gastroesophageal Reflux | 3 | 1991 | 50 | 0.190 |
Why?
| Positron-Emission Tomography | 3 | 2010 | 288 | 0.190 |
Why?
| Lung Diseases | 1 | 2002 | 96 | 0.190 |
Why?
| Kidney | 4 | 2002 | 672 | 0.180 |
Why?
| Neoplasm Recurrence, Local | 4 | 2007 | 626 | 0.180 |
Why?
| Skin | 2 | 2003 | 415 | 0.180 |
Why?
| Hernia, Inguinal | 2 | 2000 | 18 | 0.180 |
Why?
| Neutrophil Activation | 1 | 2000 | 14 | 0.180 |
Why?
| Cytoskeleton | 1 | 2000 | 41 | 0.180 |
Why?
| Prostaglandins | 1 | 2000 | 20 | 0.180 |
Why?
| Brain Edema | 3 | 2005 | 41 | 0.170 |
Why?
| Hernia, Ventral | 1 | 2000 | 7 | 0.170 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2000 | 58 | 0.170 |
Why?
| Actins | 1 | 2000 | 115 | 0.170 |
Why?
| Surgical Wound Dehiscence | 1 | 2000 | 18 | 0.170 |
Why?
| Thyroid Neoplasms | 2 | 2015 | 112 | 0.170 |
Why?
| Critical Pathways | 1 | 2000 | 37 | 0.170 |
Why?
| Wound Healing | 1 | 2001 | 201 | 0.170 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 1999 | 53 | 0.170 |
Why?
| Attitude to Health | 1 | 2001 | 190 | 0.160 |
Why?
| Population Surveillance | 1 | 2000 | 161 | 0.160 |
Why?
| Health Status | 1 | 2001 | 298 | 0.160 |
Why?
| Signal Transduction | 3 | 2015 | 1608 | 0.160 |
Why?
| Resuscitation | 2 | 1996 | 72 | 0.160 |
Why?
| Educational Measurement | 1 | 2000 | 204 | 0.160 |
Why?
| Pulmonary Artery | 1 | 2000 | 145 | 0.160 |
Why?
| Diabetes Mellitus, Experimental | 1 | 1999 | 129 | 0.160 |
Why?
| Lipopolysaccharides | 1 | 1999 | 195 | 0.160 |
Why?
| Lung Injury | 4 | 2003 | 29 | 0.150 |
Why?
| Macrophage Activation | 1 | 1998 | 25 | 0.150 |
Why?
| Students, Medical | 1 | 2000 | 159 | 0.150 |
Why?
| Macrophages, Alveolar | 1 | 1998 | 28 | 0.150 |
Why?
| Interleukin-2 | 1 | 2017 | 70 | 0.140 |
Why?
| Anal Gland Neoplasms | 1 | 1997 | 1 | 0.140 |
Why?
| Perfusion | 4 | 2002 | 48 | 0.140 |
Why?
| Breast Neoplasms | 4 | 2007 | 1184 | 0.140 |
Why?
| Middle Aged | 16 | 2011 | 12293 | 0.140 |
Why?
| Incidence | 5 | 2006 | 986 | 0.140 |
Why?
| Calcineurin | 1 | 2017 | 73 | 0.140 |
Why?
| Eukaryotic Initiation Factor-4E | 2 | 2006 | 4 | 0.130 |
Why?
| Texas | 3 | 2001 | 142 | 0.130 |
Why?
| Portal Vein | 1 | 1996 | 25 | 0.130 |
Why?
| Hepatic Artery | 1 | 1996 | 20 | 0.130 |
Why?
| Promoter Regions, Genetic | 1 | 1998 | 467 | 0.130 |
Why?
| Amino Acid Oxidoreductases | 1 | 1995 | 6 | 0.130 |
Why?
| Shock, Hemorrhagic | 1 | 1995 | 11 | 0.130 |
Why?
| Phosphorylation | 5 | 2017 | 526 | 0.130 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2015 | 23 | 0.120 |
Why?
| Apolipoproteins A | 2 | 2005 | 2 | 0.120 |
Why?
| Recurrence | 4 | 2003 | 658 | 0.120 |
Why?
| DNA-Activated Protein Kinase | 1 | 2015 | 22 | 0.120 |
Why?
| Hydroxyl Radical | 1 | 1994 | 7 | 0.120 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2015 | 33 | 0.120 |
Why?
| Complement Activation | 1 | 1994 | 24 | 0.120 |
Why?
| Postoperative Complications | 5 | 2003 | 1018 | 0.120 |
Why?
| Quality of Life | 1 | 2001 | 838 | 0.120 |
Why?
| Plasma Volume | 1 | 1994 | 4 | 0.120 |
Why?
| Contract Services | 1 | 2014 | 14 | 0.120 |
Why?
| Electrolytes | 1 | 1994 | 27 | 0.120 |
Why?
| Hemorrhage | 1 | 1996 | 194 | 0.120 |
Why?
| Gastric Fundus | 2 | 1991 | 8 | 0.120 |
Why?
| Enzyme Inhibitors | 4 | 2006 | 378 | 0.120 |
Why?
| Imidazoles | 3 | 2006 | 128 | 0.120 |
Why?
| Endotoxins | 1 | 1994 | 31 | 0.120 |
Why?
| Physician Assistants | 1 | 2014 | 18 | 0.120 |
Why?
| Multiple Trauma | 1 | 1994 | 32 | 0.120 |
Why?
| Risk Management | 1 | 2014 | 32 | 0.120 |
Why?
| Blood Volume | 1 | 1994 | 69 | 0.110 |
Why?
| Polyethylene Glycols | 1 | 1994 | 85 | 0.110 |
Why?
| Disease Models, Animal | 7 | 2004 | 1411 | 0.110 |
Why?
| Piperidines | 2 | 2005 | 96 | 0.110 |
Why?
| Nuclear Proteins | 1 | 2015 | 242 | 0.110 |
Why?
| Esophagus | 2 | 1991 | 84 | 0.110 |
Why?
| Renal Circulation | 4 | 1997 | 59 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 4 | 2006 | 1354 | 0.110 |
Why?
| Time Factors | 6 | 2006 | 2891 | 0.110 |
Why?
| Follow-Up Studies | 5 | 2005 | 2177 | 0.110 |
Why?
| Adenocarcinoma | 1 | 1997 | 402 | 0.100 |
Why?
| Proteomics | 1 | 2015 | 292 | 0.100 |
Why?
| Blood Pressure | 5 | 2000 | 519 | 0.100 |
Why?
| Heart Arrest | 2 | 2005 | 150 | 0.100 |
Why?
| Intramolecular Oxidoreductases | 3 | 1996 | 14 | 0.100 |
Why?
| Curriculum | 1 | 2014 | 397 | 0.090 |
Why?
| Risk Factors | 7 | 2007 | 3605 | 0.090 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2001 | 20 | 0.090 |
Why?
| Focal Adhesion Kinase 1 | 2 | 2001 | 15 | 0.090 |
Why?
| Enzyme Activation | 2 | 2002 | 272 | 0.090 |
Why?
| Abdominal Pain | 1 | 2011 | 84 | 0.090 |
Why?
| Aged | 8 | 2011 | 9449 | 0.090 |
Why?
| Malabsorption Syndromes | 1 | 1990 | 9 | 0.090 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 488 | 0.090 |
Why?
| Ileum | 1 | 1990 | 86 | 0.080 |
Why?
| Vascular Resistance | 2 | 2000 | 55 | 0.080 |
Why?
| Glutathione | 2 | 2005 | 296 | 0.080 |
Why?
| Pancreatic Cyst | 1 | 1988 | 11 | 0.080 |
Why?
| Chemotherapy, Adjuvant | 2 | 2001 | 121 | 0.080 |
Why?
| Random Allocation | 3 | 2004 | 285 | 0.080 |
Why?
| Recombinant Proteins | 3 | 2005 | 482 | 0.080 |
Why?
| Cysts | 1 | 1988 | 51 | 0.070 |
Why?
| Liver Diseases | 1 | 1988 | 78 | 0.070 |
Why?
| Receptors, CXCR4 | 1 | 2007 | 27 | 0.070 |
Why?
| Female | 14 | 2011 | 26576 | 0.070 |
Why?
| Nitric Oxide Donors | 2 | 2004 | 11 | 0.070 |
Why?
| Carcinoma, Hepatocellular | 1 | 2010 | 194 | 0.070 |
Why?
| Quality of Health Care | 1 | 2009 | 184 | 0.070 |
Why?
| Receptor, erbB-2 | 1 | 2007 | 74 | 0.070 |
Why?
| Eicosanoids | 2 | 1997 | 19 | 0.070 |
Why?
| Analysis of Variance | 2 | 2000 | 552 | 0.070 |
Why?
| Treatment Outcome | 6 | 2011 | 5178 | 0.070 |
Why?
| Rabbits | 2 | 2006 | 375 | 0.070 |
Why?
| Retrospective Studies | 6 | 2011 | 6124 | 0.070 |
Why?
| Carcinoma, Lobular | 1 | 2006 | 33 | 0.070 |
Why?
| Adult | 9 | 2011 | 13356 | 0.070 |
Why?
| Cohort Studies | 2 | 2001 | 1403 | 0.070 |
Why?
| Ornithine | 1 | 2006 | 18 | 0.070 |
Why?
| Colectomy | 2 | 2000 | 34 | 0.070 |
Why?
| Pancreatic Neoplasms | 1 | 1988 | 209 | 0.070 |
Why?
| Cyclic N-Oxides | 1 | 2006 | 13 | 0.070 |
Why?
| Free Radical Scavengers | 1 | 2006 | 25 | 0.070 |
Why?
| Osmolar Concentration | 1 | 2006 | 63 | 0.070 |
Why?
| Liver Neoplasms | 1 | 2010 | 329 | 0.070 |
Why?
| Chromones | 1 | 2006 | 17 | 0.070 |
Why?
| Electric Impedance | 1 | 2006 | 40 | 0.070 |
Why?
| Culture Media | 1 | 2006 | 94 | 0.060 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2006 | 90 | 0.060 |
Why?
| Morpholines | 1 | 2006 | 66 | 0.060 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 96 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2006 | 183 | 0.060 |
Why?
| Hydrogen Peroxide | 1 | 2006 | 114 | 0.060 |
Why?
| Chromatography | 1 | 2005 | 12 | 0.060 |
Why?
| Indomethacin | 3 | 2000 | 38 | 0.060 |
Why?
| Cell Separation | 1 | 2005 | 89 | 0.060 |
Why?
| Pyridines | 2 | 2003 | 133 | 0.060 |
Why?
| Aged, 80 and over | 4 | 2011 | 3138 | 0.060 |
Why?
| United States | 2 | 2009 | 4883 | 0.060 |
Why?
| Neoplasm Staging | 4 | 2010 | 749 | 0.060 |
Why?
| Asphyxia | 1 | 2004 | 9 | 0.060 |
Why?
| Umbilical Veins | 2 | 2002 | 23 | 0.060 |
Why?
| Disease-Free Survival | 2 | 2007 | 450 | 0.060 |
Why?
| Nitroso Compounds | 1 | 2004 | 4 | 0.060 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2004 | 50 | 0.060 |
Why?
| Referral and Consultation | 1 | 2006 | 285 | 0.060 |
Why?
| Colitis | 1 | 2004 | 51 | 0.060 |
Why?
| Vagotomy | 1 | 2003 | 5 | 0.060 |
Why?
| Glucose | 1 | 2006 | 337 | 0.060 |
Why?
| rho GTP-Binding Proteins | 1 | 2003 | 6 | 0.060 |
Why?
| Lymph Nodes | 1 | 2005 | 257 | 0.050 |
Why?
| Prognosis | 3 | 2007 | 1957 | 0.050 |
Why?
| Mesenteric Arteries | 3 | 1998 | 46 | 0.050 |
Why?
| Epithelial Cells | 2 | 2004 | 209 | 0.050 |
Why?
| Hematocrit | 1 | 2003 | 43 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2003 | 94 | 0.050 |
Why?
| Vitamin D-Binding Protein | 1 | 2003 | 9 | 0.050 |
Why?
| Accidents, Traffic | 1 | 2003 | 87 | 0.050 |
Why?
| Myocardial Reperfusion Injury | 1 | 2003 | 48 | 0.050 |
Why?
| Aorta | 4 | 1998 | 162 | 0.050 |
Why?
| Anti-Inflammatory Agents | 1 | 2004 | 160 | 0.050 |
Why?
| Blood Proteins | 1 | 2003 | 77 | 0.050 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2003 | 64 | 0.050 |
Why?
| Helicobacter pylori | 1 | 2003 | 66 | 0.050 |
Why?
| Dinoprost | 2 | 2000 | 7 | 0.050 |
Why?
| Helicobacter Infections | 1 | 2003 | 64 | 0.050 |
Why?
| Tissue Donors | 1 | 2003 | 111 | 0.050 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2002 | 7 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2003 | 212 | 0.050 |
Why?
| Mice | 4 | 2006 | 5658 | 0.050 |
Why?
| Receptors, Angiotensin | 1 | 2002 | 13 | 0.050 |
Why?
| Receptors, Thromboxane | 1 | 2002 | 3 | 0.050 |
Why?
| Dextrans | 1 | 2002 | 18 | 0.050 |
Why?
| Brain Ischemia | 1 | 2004 | 157 | 0.050 |
Why?
| Hypertension, Renovascular | 1 | 2002 | 14 | 0.050 |
Why?
| Emergencies | 1 | 2003 | 84 | 0.050 |
Why?
| Adrenal Glands | 1 | 2002 | 40 | 0.050 |
Why?
| Flavonoids | 1 | 2002 | 39 | 0.050 |
Why?
| Myocardial Ischemia | 1 | 2003 | 117 | 0.050 |
Why?
| Tyrosine | 1 | 2002 | 95 | 0.050 |
Why?
| Bronchi | 1 | 2002 | 43 | 0.050 |
Why?
| Survival Rate | 2 | 2005 | 905 | 0.050 |
Why?
| Renin-Angiotensin System | 1 | 2002 | 59 | 0.050 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 122 | 0.050 |
Why?
| Interleukin-1 | 1 | 2002 | 106 | 0.050 |
Why?
| Drug Synergism | 1 | 2002 | 152 | 0.050 |
Why?
| Rats, Wistar | 1 | 2002 | 221 | 0.050 |
Why?
| Intestinal Mucosa | 3 | 2004 | 215 | 0.050 |
Why?
| Isomerases | 3 | 1996 | 3 | 0.050 |
Why?
| Capillaries | 2 | 1998 | 50 | 0.050 |
Why?
| Inflammation Mediators | 1 | 2002 | 110 | 0.050 |
Why?
| Hospitals, Teaching | 1 | 2001 | 53 | 0.050 |
Why?
| Hospitals, Veterans | 1 | 2001 | 110 | 0.050 |
Why?
| Cell Membrane | 1 | 2002 | 249 | 0.050 |
Why?
| Gynecomastia | 1 | 2001 | 4 | 0.050 |
Why?
| Breast Neoplasms, Male | 1 | 2001 | 6 | 0.050 |
Why?
| Enzyme Induction | 1 | 2001 | 79 | 0.050 |
Why?
| Organ Culture Techniques | 1 | 2001 | 48 | 0.050 |
Why?
| Chronic Disease | 2 | 2002 | 566 | 0.050 |
Why?
| Vasodilator Agents | 2 | 2005 | 98 | 0.050 |
Why?
| Oxidative Stress | 1 | 2005 | 759 | 0.050 |
Why?
| Superoxides | 2 | 1998 | 46 | 0.050 |
Why?
| Surgical Procedures, Operative | 1 | 2001 | 66 | 0.050 |
Why?
| Alanine Transaminase | 2 | 2004 | 117 | 0.050 |
Why?
| Reference Values | 2 | 2004 | 302 | 0.050 |
Why?
| Myocardium | 1 | 2003 | 443 | 0.050 |
Why?
| Up-Regulation | 1 | 2002 | 446 | 0.050 |
Why?
| Demography | 1 | 2001 | 93 | 0.040 |
Why?
| Documentation | 1 | 2000 | 33 | 0.040 |
Why?
| Integrins | 1 | 2000 | 30 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2003 | 550 | 0.040 |
Why?
| Mammography | 1 | 2001 | 98 | 0.040 |
Why?
| Sex Distribution | 1 | 2000 | 135 | 0.040 |
Why?
| Age Distribution | 1 | 2000 | 169 | 0.040 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 1996 | 194 | 0.040 |
Why?
| Extravascular Lung Water | 1 | 1999 | 2 | 0.040 |
Why?
| Cell Movement | 1 | 2001 | 245 | 0.040 |
Why?
| Apoptosis | 1 | 2005 | 1092 | 0.040 |
Why?
| Neutrophil Infiltration | 1 | 1999 | 26 | 0.040 |
Why?
| Colon | 2 | 2004 | 96 | 0.040 |
Why?
| Pulmonary Alveoli | 1 | 1999 | 27 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2000 | 103 | 0.040 |
Why?
| Rats, Zucker | 1 | 1999 | 67 | 0.040 |
Why?
| Interprofessional Relations | 1 | 2000 | 85 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2000 | 147 | 0.040 |
Why?
| Microspheres | 2 | 1996 | 26 | 0.040 |
Why?
| Faculty, Medical | 1 | 2000 | 92 | 0.040 |
Why?
| Glutathione Disulfide | 2 | 2005 | 40 | 0.040 |
Why?
| 6-Ketoprostaglandin F1 alpha | 2 | 1996 | 6 | 0.040 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 1996 | 18 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2000 | 269 | 0.040 |
Why?
| Regional Blood Flow | 2 | 1996 | 106 | 0.040 |
Why?
| Body Fluids | 1 | 1998 | 20 | 0.040 |
Why?
| Collagen | 1 | 2000 | 208 | 0.040 |
Why?
| Sensitivity and Specificity | 3 | 2010 | 858 | 0.040 |
Why?
| Specific Pathogen-Free Organisms | 1 | 1998 | 14 | 0.040 |
Why?
| Wounds, Stab | 1 | 1998 | 6 | 0.040 |
Why?
| Sex | 1 | 1998 | 1 | 0.040 |
Why?
| Student Dropouts | 1 | 1998 | 3 | 0.040 |
Why?
| Sequence Homology | 1 | 1998 | 17 | 0.040 |
Why?
| Integrin alphaV | 1 | 1998 | 3 | 0.040 |
Why?
| Proteins | 2 | 1998 | 347 | 0.040 |
Why?
| Length of Stay | 3 | 2011 | 624 | 0.040 |
Why?
| Luciferases | 1 | 1998 | 50 | 0.040 |
Why?
| Epidermal Growth Factor | 1 | 1998 | 33 | 0.040 |
Why?
| Glucuronidase | 1 | 1998 | 48 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 96 | 0.040 |
Why?
| Antineoplastic Agents | 2 | 2003 | 1175 | 0.040 |
Why?
| Microscopy, Fluorescence | 1 | 1998 | 164 | 0.040 |
Why?
| Aortic Aneurysm | 1 | 1998 | 25 | 0.040 |
Why?
| Blood Coagulation | 1 | 1998 | 58 | 0.040 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 1988 | 90 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 824 | 0.040 |
Why?
| NFATC Transcription Factors | 1 | 2017 | 23 | 0.040 |
Why?
| Lysosomes | 1 | 1998 | 86 | 0.040 |
Why?
| Jurkat Cells | 1 | 2017 | 28 | 0.040 |
Why?
| Active Transport, Cell Nucleus | 1 | 2017 | 33 | 0.040 |
Why?
| DNA, Single-Stranded | 1 | 1998 | 89 | 0.040 |
Why?
| Reoperation | 1 | 2000 | 454 | 0.040 |
Why?
| Protein Stability | 1 | 2017 | 42 | 0.040 |
Why?
| Transfection | 1 | 1998 | 354 | 0.040 |
Why?
| Registries | 1 | 2000 | 523 | 0.040 |
Why?
| Arginine | 2 | 1996 | 178 | 0.040 |
Why?
| Binding Sites | 1 | 1998 | 378 | 0.040 |
Why?
| Radiopharmaceuticals | 2 | 2010 | 205 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2017 | 121 | 0.040 |
Why?
| Gene Deletion | 1 | 1998 | 267 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 1997 | 60 | 0.040 |
Why?
| Permeability | 1 | 1997 | 68 | 0.030 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2010 | 191 | 0.030 |
Why?
| Base Sequence | 1 | 1998 | 657 | 0.030 |
Why?
| Hemodynamics | 3 | 2004 | 263 | 0.030 |
Why?
| Oligopeptides | 1 | 2017 | 93 | 0.030 |
Why?
| Molecular Sequence Data | 1 | 1998 | 799 | 0.030 |
Why?
| Multiple Myeloma | 1 | 2011 | 2916 | 0.030 |
Why?
| Brain | 1 | 2005 | 1310 | 0.030 |
Why?
| Ultrasonography | 2 | 1988 | 429 | 0.030 |
Why?
| Age Factors | 1 | 2000 | 1092 | 0.030 |
Why?
| Parenteral Nutrition, Total | 1 | 1996 | 31 | 0.030 |
Why?
| Protein Processing, Post-Translational | 1 | 2017 | 154 | 0.030 |
Why?
| Cesium Radioisotopes | 1 | 1996 | 4 | 0.030 |
Why?
| Ruthenium Radioisotopes | 1 | 1996 | 2 | 0.030 |
Why?
| Prospective Studies | 3 | 2007 | 2345 | 0.030 |
Why?
| Evans Blue | 1 | 1995 | 2 | 0.030 |
Why?
| Platelet Activating Factor | 1 | 1995 | 2 | 0.030 |
Why?
| Mesenteric Artery, Superior | 1 | 1995 | 10 | 0.030 |
Why?
| Sepsis | 1 | 1998 | 220 | 0.030 |
Why?
| Hospital Mortality | 2 | 2011 | 409 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1037 | 0.030 |
Why?
| Gallbladder | 1 | 1995 | 25 | 0.030 |
Why?
| Hospitalization | 1 | 2000 | 663 | 0.030 |
Why?
| DNA-Binding Proteins | 1 | 1998 | 424 | 0.030 |
Why?
| Adenosine Triphosphate | 2 | 1996 | 231 | 0.030 |
Why?
| Chemotactic Factors | 1 | 1994 | 5 | 0.030 |
Why?
| Complement C5a | 1 | 1994 | 4 | 0.030 |
Why?
| Deferoxamine | 1 | 1994 | 10 | 0.030 |
Why?
| Thiourea | 1 | 1994 | 9 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 1996 | 131 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 1997 | 638 | 0.030 |
Why?
| Cell Differentiation | 2 | 2010 | 649 | 0.030 |
Why?
| Gene Expression | 1 | 2017 | 612 | 0.030 |
Why?
| Complement System Proteins | 1 | 1994 | 31 | 0.030 |
Why?
| Serum Albumin, Radio-Iodinated | 1 | 1994 | 1 | 0.030 |
Why?
| Therapeutic Irrigation | 1 | 1994 | 27 | 0.030 |
Why?
| Polymyxin B | 1 | 1994 | 5 | 0.030 |
Why?
| Estrogens | 1 | 1996 | 222 | 0.030 |
Why?
| Tomography, X-Ray Computed | 3 | 1988 | 1153 | 0.030 |
Why?
| Drug Tolerance | 1 | 1994 | 59 | 0.030 |
Why?
| Child, Preschool | 3 | 1991 | 3879 | 0.030 |
Why?
| Models, Biological | 1 | 1996 | 719 | 0.030 |
Why?
| Indoles | 1 | 2015 | 273 | 0.030 |
Why?
| Lipid Peroxides | 1 | 1991 | 10 | 0.020 |
Why?
| Infant | 2 | 1991 | 3575 | 0.020 |
Why?
| Enterocolitis, Neutropenic | 1 | 2011 | 6 | 0.020 |
Why?
| Predictive Value of Tests | 2 | 2007 | 907 | 0.020 |
Why?
| Cytokines | 1 | 1994 | 607 | 0.020 |
Why?
| Ileus | 1 | 2011 | 15 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2015 | 1388 | 0.020 |
Why?
| Postoperative Care | 1 | 1991 | 104 | 0.020 |
Why?
| Patient Transfer | 1 | 2011 | 94 | 0.020 |
Why?
| Enteral Nutrition | 1 | 1991 | 148 | 0.020 |
Why?
| Gastrointestinal Transit | 1 | 1990 | 4 | 0.020 |
Why?
| Enema | 1 | 1990 | 9 | 0.020 |
Why?
| Barium Sulfate | 1 | 1990 | 12 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 2 | 2003 | 168 | 0.020 |
Why?
| Adenomatous Polyposis Coli | 1 | 1990 | 7 | 0.020 |
Why?
| Blotting, Western | 2 | 2005 | 587 | 0.020 |
Why?
| Intestinal Absorption | 1 | 1990 | 46 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2010 | 15 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 463 | 0.020 |
Why?
| Dogs | 1 | 1990 | 185 | 0.020 |
Why?
| Colitis, Ulcerative | 1 | 1990 | 51 | 0.020 |
Why?
| Diarrhea | 1 | 1990 | 90 | 0.020 |
Why?
| Child | 3 | 1991 | 6849 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 1989 | 108 | 0.020 |
Why?
| Patient Discharge | 1 | 2011 | 318 | 0.020 |
Why?
| Survival Analysis | 2 | 2003 | 670 | 0.020 |
Why?
| Adolescent | 2 | 1991 | 6417 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2004 | 1777 | 0.020 |
Why?
| Weight Gain | 1 | 1990 | 230 | 0.020 |
Why?
| Angiography | 1 | 1988 | 127 | 0.020 |
Why?
| Neoplasms | 1 | 1998 | 1234 | 0.020 |
Why?
| Intraoperative Complications | 1 | 1989 | 113 | 0.020 |
Why?
| Aorta, Abdominal | 2 | 1998 | 41 | 0.020 |
Why?
| Pyloric Antrum | 1 | 1986 | 11 | 0.020 |
Why?
| Cytomegalovirus Infections | 1 | 1986 | 35 | 0.020 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 52 | 0.020 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 1996 | 24 | 0.020 |
Why?
| Mastectomy, Extended Radical | 1 | 2005 | 1 | 0.020 |
Why?
| tert-Butylhydroperoxide | 1 | 2005 | 5 | 0.020 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2005 | 6 | 0.020 |
Why?
| Apolipoprotein A-I | 1 | 2005 | 7 | 0.020 |
Why?
| PC12 Cells | 1 | 2005 | 26 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 102 | 0.020 |
Why?
| Biopsy, Fine-Needle | 1 | 2006 | 108 | 0.020 |
Why?
| Mitosis | 1 | 2005 | 88 | 0.020 |
Why?
| Thioglycolates | 1 | 2005 | 5 | 0.020 |
Why?
| Cell Size | 1 | 2005 | 46 | 0.020 |
Why?
| Cell Count | 1 | 2005 | 147 | 0.010 |
Why?
| Dextran Sulfate | 1 | 2004 | 10 | 0.010 |
Why?
| Lymphatic Metastasis | 1 | 2005 | 226 | 0.010 |
Why?
| Platelet Adhesiveness | 1 | 2004 | 13 | 0.010 |
Why?
| Indicators and Reagents | 1 | 2004 | 37 | 0.010 |
Why?
| Heart Arrest, Induced | 1 | 2004 | 7 | 0.010 |
Why?
| Polyamines | 1 | 2004 | 9 | 0.010 |
Why?
| P-Selectin | 1 | 2004 | 32 | 0.010 |
Why?
| Disease Progression | 1 | 2007 | 820 | 0.010 |
Why?
| Oxidation-Reduction | 1 | 2005 | 315 | 0.010 |
Why?
| Leukocytes | 1 | 2004 | 66 | 0.010 |
Why?
| Extracorporeal Circulation | 1 | 2003 | 9 | 0.010 |
Why?
| Blood Gas Analysis | 1 | 2003 | 29 | 0.010 |
Why?
| Aspartate Aminotransferases | 1 | 2004 | 43 | 0.010 |
Why?
| Probability | 1 | 2004 | 163 | 0.010 |
Why?
| Decanoic Acids | 1 | 2003 | 1 | 0.010 |
Why?
| Alkenes | 1 | 2003 | 3 | 0.010 |
Why?
| Hydroxy Acids | 1 | 2003 | 8 | 0.010 |
Why?
| Mice, Inbred NOD | 1 | 2004 | 94 | 0.010 |
Why?
| ADP Ribose Transferases | 1 | 2003 | 4 | 0.010 |
Why?
| Botulinum Toxins | 1 | 2003 | 5 | 0.010 |
Why?
| Down-Regulation | 1 | 2005 | 342 | 0.010 |
Why?
| Amides | 1 | 2003 | 36 | 0.010 |
Why?
| Mice, Inbred Strains | 1 | 2003 | 160 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2003 | 78 | 0.010 |
Why?
| Cattle | 1 | 2003 | 207 | 0.010 |
Why?
| Autocrine Communication | 1 | 2002 | 8 | 0.010 |
Why?
| Radioimmunoassay | 1 | 2002 | 44 | 0.010 |
Why?
| Cardiopulmonary Resuscitation | 1 | 2004 | 138 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2003 | 193 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2006 | 1182 | 0.010 |
Why?
| Kidney Tubules, Proximal | 1 | 2002 | 62 | 0.010 |
Why?
| src-Family Kinases | 1 | 2002 | 51 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2003 | 543 | 0.010 |
Why?
| Mice, Knockout | 1 | 2004 | 835 | 0.010 |
Why?
| Angiotensin II | 1 | 2002 | 162 | 0.010 |
Why?
| Odds Ratio | 1 | 2003 | 548 | 0.010 |
Why?
| Pyrimidines | 1 | 2002 | 192 | 0.010 |
Why?
| Heart | 1 | 2003 | 336 | 0.010 |
Why?
| Cell Line | 1 | 2003 | 1010 | 0.010 |
Why?
| Regression Analysis | 1 | 2001 | 385 | 0.010 |
Why?
| Models, Theoretical | 1 | 2001 | 172 | 0.010 |
Why?
| Echocardiography | 1 | 2003 | 382 | 0.010 |
Why?
| Hospitals | 1 | 2001 | 172 | 0.010 |
Why?
| Inflammation | 1 | 2004 | 603 | 0.010 |
Why?
| Myocardial Infarction | 1 | 2003 | 391 | 0.010 |
Why?
| Case-Control Studies | 1 | 2003 | 1129 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2002 | 972 | 0.010 |
Why?
| Ligation | 1 | 1998 | 61 | 0.010 |
Why?
| Cecum | 1 | 1998 | 59 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 1998 | 66 | 0.010 |
Why?
| Allopurinol | 1 | 1997 | 6 | 0.010 |
Why?
| Inulin | 1 | 1997 | 9 | 0.010 |
Why?
| Pentoxifylline | 1 | 1997 | 13 | 0.010 |
Why?
| Arterial Occlusive Diseases | 1 | 1998 | 79 | 0.010 |
Why?
| Sodium | 1 | 1997 | 92 | 0.010 |
Why?
| Femoral Artery | 1 | 1998 | 102 | 0.010 |
Why?
| Career Choice | 1 | 1998 | 110 | 0.010 |
Why?
| Family | 1 | 1998 | 177 | 0.010 |
Why?
| Cyclooxygenase 1 | 1 | 1996 | 5 | 0.010 |
Why?
| Constriction | 1 | 1996 | 9 | 0.010 |
Why?
| Immunoenzyme Techniques | 1 | 1996 | 141 | 0.010 |
Why?
| Testosterone | 1 | 1996 | 137 | 0.010 |
Why?
| Vascular Surgical Procedures | 1 | 1998 | 164 | 0.010 |
Why?
| Isoenzymes | 1 | 1996 | 168 | 0.010 |
Why?
| Cholecystitis | 1 | 1995 | 12 | 0.010 |
Why?
| Parenteral Nutrition | 1 | 1995 | 26 | 0.010 |
Why?
| Immunoblotting | 1 | 1995 | 116 | 0.010 |
Why?
| Estradiol | 1 | 1996 | 213 | 0.010 |
Why?
| Antibodies | 1 | 1995 | 151 | 0.010 |
Why?
| Homeostasis | 1 | 1996 | 202 | 0.010 |
Why?
| Membrane Proteins | 1 | 1996 | 347 | 0.010 |
Why?
| Rats, Inbred Strains | 1 | 1992 | 197 | 0.010 |
Why?
| Radiography | 1 | 1989 | 485 | 0.000 |
Why?
| Homosexuality | 1 | 1986 | 4 | 0.000 |
Why?
| Stomach Diseases | 1 | 1986 | 13 | 0.000 |
Why?
| Endoscopy | 1 | 1986 | 118 | 0.000 |
Why?
| Gastrointestinal Diseases | 1 | 1986 | 128 | 0.000 |
Why?
|
|
Turnage's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|